Teva Pharmaceutical Industries Limited
TEVJF
$16.11
$2.3116.74%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 198.62% | 50.34% | 48.35% | -508.63% | -130.02% |
| Total Depreciation and Amortization | -9.29% | 3.86% | 0.00% | -4.78% | 2.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -82.16% | 38.63% | -20.86% | 191.67% | 47.24% |
| Change in Net Operating Assets | -185.71% | -177.29% | 3,270.00% | 97.99% | -270.21% |
| Cash from Operations | -118.26% | -17.03% | 572.82% | 183.06% | -110.47% |
| Capital Expenditure | 1.55% | 12.84% | -52.58% | 21.77% | -4.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 325.00% | -89.47% | 3,700.00% | -- | -- |
| Other Investing Activities | -4.89% | -13.49% | 37.96% | -3.18% | -32.62% |
| Cash from Investing | -0.50% | -24.63% | 50.56% | 23.61% | -52.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -99.71% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,518.18% | -- | -- | 93.38% | -98.68% |
| Cash from Financing | -158.75% | -- | -- | -539.74% | 73.78% |
| Foreign Exchange rate Adjustments | 137.19% | -221.00% | 304.08% | 52.88% | -252.94% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | 200.00% | -- |
| Net Change in Cash | -8,336.84% | -101.79% | 244.75% | -210.59% | -124.16% |